ATTRV122I Amyloidosis

ATTRV122I amyloidosis is a genetic disease where a small change in the transthyretin (TTR) gene (valine → isoleucine at position 122; sometimes numbered 142) makes the TTR protein less stable. The weakened protein falls apart, misfolds, and forms amyloid fibrils that deposit mostly in the heart muscle. Over time, these deposits make the heart thick, stiff, and less able to relax and pump. Many people develop a restrictive cardiomyopathy and heart failure, usually later in adult life. The disease shows incomplete and late-onset penetrance—meaning some carriers never get sick, and those who do often develop symptoms in later years. This variant is most common in people of African ancestry. NCBI+2AHA Journals+2

ATTRV122I amyloidosis is a genetic form of transthyretin (TTR) amyloidosis in which a small change in the TTR gene (valine→isoleucine at position 122; also called Val142Ile) makes the TTR protein unstable. Over many years, unstable TTR forms amyloid “fibers” that gradually build up in the heart muscle. This makes the heart stiff (a restrictive cardiomyopathy), so it can’t fill and pump normally. Symptoms usually appear later in adult life and often look like typical heart-failure symptoms at first (breathlessness, swelling, fatigue). The V122I variant is the most common hereditary cause of cardiac amyloidosis worldwide, especially in people of West African ancestry, where about 3–4% carry the variant. Not everyone with the variant gets disease, but the risk of heart failure and death is higher with age. Early recognition matters because several modern medicines can slow progression and improve outcomes. JACC+3PMC+3PMC+3

What is happening inside the body

TTR is a protein made by the liver that normally carries thyroid hormone and vitamin A-binding protein in blood. The V122I change weakens the “tetramer” structure of TTR so it falls apart more easily; single pieces misfold, then stack into amyloid fibers that deposit mostly in the heart walls. The heart becomes thick and stiff, electrical signals travel abnormally, and pressures rise. Over time this causes heart failure with preserved or mildly reduced ejection fraction, rhythm problems (like atrial fibrillation), conduction disease, and fluid retention. Some people have carpal tunnel or biceps tendon issues years earlier. Medicines now target stabilizing TTR, silencing hepatic TTR production, or (in trials) gene editing to reduce TTR. JACC+2American College of Cardiology+2

Other names

Doctors and articles may also call it: TTR V122I amyloidosis, p.V142I ATTR, Val122Ile ATTR, hereditary (variant) transthyretin cardiac amyloidosis due to V122I, or ATTRv (V122I). All of these mean the same disease: a hereditary TTR amyloidosis dominated by heart involvement caused by the V122I (V142I) change. NCBI+1

Types

Even though the gene change is the same, people can present in a few patterns:

• Cardiac-predominant (most common in V122I): main damage is in the heart, with thick walls, stiff filling, and gradually worsening shortness of breath, swelling, and fatigue. NCBI+1

• Mixed phenotype (less common with V122I): some people also have nerve, eye, or kidney features, because TTR amyloid can deposit in many organs; this is far more typical of other TTR variants but can be seen variably. NCBI

• Heterozygous vs. homozygous: most affected people carry one V122I copy (heterozygous). Two copies (homozygous) are rare and often lead to earlier and more severe heart disease. ScienceDirect

Causes

“Cause” here means both the root cause (the gene change) and the factors that drive or modify disease onset, severity, and progression.

1. TTR V122I gene variant: the primary cause; it destabilizes the TTR tetramer. New England Journal of Medicine

2. Tetramer dissociation: V122I makes TTR fall apart into monomers that misfold. New England Journal of Medicine

3. Amyloid fibril formation in the heart: misfolded TTR builds stiff deposits in the myocardium. NCBI

4. Age (late onset): risk of clinical disease rises with age; penetrance is incomplete until later life. AHA Journals

5. Genetic background/ancestry: variant is enriched in people of African ancestry; population risk is therefore higher. PubMed

6. Male sex (observationally higher clinical burden) in many cohorts of cardiac ATTR. AHA Journals

7. Homozygosity (two variant copies) increases severity and earlier presentation. ScienceDirect

8. Cardiac afterload/stress over time (e.g., longstanding hypertension may mask amyloidosis and burden a stiff heart). AHA Journals

9. Wild-type TTR co-deposition: even with a variant, native TTR can join the fibrils and add to load. AHA Journals

10. Chronic diastolic dysfunction cycle: stiffness → congestion → neurohormonal stress → more dysfunction. AHA Journals

11. Conduction system infiltration causing brady- or tachyarrhythmias that worsen heart failure. Orpha

12. Coexisting monoclonal proteins (MGUS/AL) can complicate diagnosis and delay correct therapy. JACC

13. Delayed recognition (mislabeling as “hypertensive heart disease” or “HFpEF of aging”) allows progression. AHA Journals

14. Myocardial extracellular volume expansion (revealed by CMR) reflects amyloid load and drives stiffness. AHA Journals

15. Impaired longitudinal strain (apical sparing pattern) signals early mechanical injury typical of cardiac amyloid. PMC+1

16. Systemic deposition potential (tendons, ligaments) can add morbidity (e.g., carpal tunnel in ATTR in general). NCBI

17. HFpEF biology: V122I ATTR is a recognized cause of HFpEF in older adults. JAMA Network

18. Biochemical injury (elevated troponin/NT-proBNP) reflects ongoing cardiomyocyte stress from deposits. AHA Journals

19. Autonomic involvement (less prominent than neuropathic variants but may occur) worsening exercise capacity. NCBI

20. Socio-diagnostic factors (limited access to specialized testing) delay care in high-risk communities. JAMA Network

Symptoms

1. Shortness of breath with activity due to a stiff heart that cannot fill well. AHA Journals

2. Leg and ankle swelling from fluid buildup when the heart is congested. AHA Journals

3. Fatigue and low energy from reduced forward flow and poor oxygen delivery. AHA Journals

4. Orthopnea (breathlessness when lying flat) because fluid shifts toward the lungs. AHA Journals

5. Paroxysmal nocturnal dyspnea (sudden night breathlessness) from rising left-sided pressures. AHA Journals

6. Palpitations from atrial fibrillation or other rhythm problems caused by amyloid in the conduction system. Orpha

7. Lightheadedness or fainting if the heart rate is too slow or too fast, or if blood pressure drops. Orpha

8. Chest pressure with exertion from high filling pressures rather than blocked arteries. AHA Journals

9. Early satiety/abdominal fullness from congestion of the liver and gut veins. AHA Journals

10. Unintentional weight loss in advanced disease due to chronic illness and poor appetite. AHA Journals

11. Edema around the eyes or generalized swelling when fluid retention is significant. AHA Journals

12. Carpal tunnel symptoms (numbness/tingling) can occur in ATTR broadly; less specific for V122I but possible. NCBI

13. Reduced exercise capacity measured on walk tests because the heart cannot increase filling. AHA Journals

14. Constitutional symptoms (low-grade malaise) sometimes accompany chronic cardiac amyloid. AHA Journals

15. Signs of right-sided failure (neck vein distention, liver enlargement) in advanced stages. AHA Journals

Diagnostic tests

A) Physical examination

1. Neck vein exam (JVP): A raised jugular venous pressure suggests high right-sided filling pressures from a stiff heart. It helps stage congestion at the bedside. AHA Journals

2. Peripheral edema check: Pitting edema at the ankles/legs indicates fluid retention from heart failure due to amyloid infiltration. AHA Journals

3. Auscultation for S3/S4 and murmurs: Extra heart sounds reflect poor relaxation and non-compliant ventricles; murmurs may relate to thickened valves or high pressures. AHA Journals

4. Blood pressure and orthostatic vitals: Low or dropping pressures (especially with standing) plus heart failure signs raise suspicion for infiltrative cardiomyopathy. AHA Journals

5. Liver size and ascites assessment: Hepatic congestion and fluid in the abdomen indicate advanced right-sided involvement. AHA Journals

B) Manual/bedside functional tests

6. 6-minute walk test: Tracks exercise capacity over time; reduced distance is common in cardiac amyloidosis and helps follow response to therapy. AHA Journals

7. Grip strength or frailty screens: Simple tools to gauge systemic impact and reserve in older patients with restrictive cardiomyopathy. AHA Journals

8. Bedside diuretic response test: Careful observation of weight/edema and symptoms after low-dose diuretics helps judge congestion control in a stiff heart. AHA Journals

C) Laboratory and pathological tests

9. Cardiac biomarkers (NT-proBNP, troponin): Usually elevated; track disease severity and prognosis. AHA Journals

10. AL exclusion panel (serum/urine immunofixation + serum free light chains): First rule-out step; if negative, ATTR is more likely, and nuclear amyloid scans become highly specific. NCBI

11. Genetic testing for TTR V122I (p.V142I): Confirms the hereditary variant for the patient and family. NCBI

12. Endomyocardial biopsy with Congo red and TTR typing (mass spectrometry): Gold-standard proof when diagnosis is uncertain or scans are discordant. AHA Journals

13. Serum/urine protein studies for monoclonal gammopathy: Even with ATTR, a coexisting monoclonal protein can mislead; checking avoids misclassification as AL. JACC

14. Basic metabolic panel, liver and kidney tests: Evaluate organ congestion and guide safe diuretic use. AHA Journals

D) Electrodiagnostic and ECG-based tests

15. 12-lead ECG: May show low limb-lead voltages despite thick heart walls, conduction blocks, or atrial fibrillation—findings that support an infiltrative process. AHA Journals

16. Holter or event monitoring: Detects intermittent arrhythmias and pauses that explain palpitations or syncope; guides need for rhythm therapy or pacemaker. AHA Journals

17. Signal-averaged or advanced ECG analysis (select centers): Research and specialty tools can quantify conduction disease burden in amyloid hearts. AHA Journals

E) Imaging tests

18. Echocardiography with strain: Shows thick walls, small cavity, diastolic dysfunction, and often apical sparing of longitudinal strain—an important clue to amyloidosis (helpful but not perfectly specific). PMC+2JACC+2

19. Cardiac MRI (CMR): Demonstrates diffuse or subendocardial late gadolinium enhancement and high extracellular volume, reflecting amyloid infiltration. AHA Journals

20. 99mTc-PYP (or DPD/HMDP) bone scintigraphy with SPECT: If AL tests are negative, a strong cardiac uptake on these scans can diagnose ATTR non-invasively with high accuracy; multicenter data support its utility. PubMed+1

Non-pharmacological treatments

1. Low-salt eating (2 g sodium/day or less)
   Description: Choose fresh foods; avoid added salt, canned soups, pickles, chips. Read labels for sodium.
   Purpose: Reduce fluid retention and shortness of breath.
   Mechanism: Less sodium → less water held in the body → easier heart filling. Expert pathways make meticulous volume control the cornerstone. ijcscardiol.org

2. Fluid awareness (daily weights)
   Description: Weigh every morning; call the care team if +1–2 kg in 1–3 days.
   Purpose: Catch fluid build-up early.
   Mechanism: Tracks congestion so diuretics can be adjusted promptly. ijcscardiol.org

3. Judicious physical activity / cardiac rehab
   Description: Gentle, supervised aerobic and light resistance training tailored to symptoms.
   Purpose: Maintain stamina and independence, avoid deconditioning.
   Mechanism: Improves peripheral conditioning without stressing the stiff heart. Consensus documents endorse individualized plans. JACC

4. Compression stockings & leg elevation
   Description: Graduated compression during the day; elevate legs when resting.
   Purpose: Reduce ankle swelling.
   Mechanism: Supports venous return, counters edema from high filling pressures. JACC

5. Sleep apnea screening and CPAP when indicated
   Description: Ask about snoring/daytime sleepiness; do a sleep study if suspected.
   Purpose: Improve energy, rhythm stability, and blood pressure.
   Mechanism: Treating apnea lowers nocturnal hypoxia and cardiac stress. JACC

6. Atrial fibrillation self-monitoring
   Description: Learn to check pulse; report palpitations, dizziness, or reduced exercise tolerance.
   Purpose: Early detection of AF to guide anticoagulation and rhythm care.
   Mechanism: AF is common in ATTR-CM; timely treatment prevents stroke/worsening HF. American College of Cardiology

7. Medication review to avoid “provocateurs”
   Description: Limit/avoid NSAIDs; be cautious with high-dose beta-blockers, nondihydropyridine calcium channel blockers, and digoxin unless specialist advises.
   Purpose: Prevent hypotension, low output, or drug-amyloid interactions.
   Mechanism: Amyloid hearts are heart-rate–dependent; several HF drugs are poorly tolerated. AHA Journals+1

8. Vaccinations (influenza, COVID-19, pneumococcal)
   Description: Keep up to date per local guidelines.
   Purpose: Reduce infection-related decompensation.
   Mechanism: Infections trigger fluid shifts and HF exacerbations. JACC

9. Genetic counseling & family cascade testing
   Description: Offer TTR testing to adult relatives once a V122I proband is confirmed.
   Purpose: Early identification and monitoring.
   Mechanism: Detects carriers who may benefit from surveillance and education. NCBI

10. Education on heat, dehydration, and travel
    Description: Plan fluid/diuretic use; avoid extreme heat; bring medication lists when traveling.
    Purpose: Prevent decompensation away from care.
    Mechanism: Stable salt–water balance avoids admissions. JACC

11. Heart-healthy nutrition (whole foods pattern)
    Description: Emphasize vegetables, fruits, legumes, fish, whole grains; moderate portions; limit alcohol.
    Purpose: Support blood pressure, kidney function, and weight.
    Mechanism: Lowers congestion drivers and comorbidity burden. JACC

12. Falls prevention / orthostatic care
    Description: Rise slowly; review drugs that lower BP; consider compression and hydration strategy.
    Purpose: Reduce fainting or falls from autonomic dysfunction.
    Mechanism: Stabilizes BP and perfusion. JACC

13. Early rhythm-control strategy discussion
    Description: For symptomatic AF, consider antiarrhythmic drugs or ablation instead of just rate control.
    Purpose: Amyloid patients often tolerate rate-slowing drugs poorly.
    Mechanism: Restoring sinus rhythm may improve filling and output. Frontiers

14. Anticoagulation literacy
    Description: If you have AF/flutter, understand stroke prevention and medicine adherence.
    Purpose: Prevent stroke, which is more common with amyloidosis.
    Mechanism: AF + stiff atria → clot risk ↑; anticoagulation reduces it. American College of Cardiology

15. Care at an amyloidosis-experienced center
    Description: Seek clinics with nuclear cardiology/CMR and amyloid expertise.
    Purpose: Faster, safer diagnosis and access to modern therapies/clinical trials.
    Mechanism: Streamlined non-biopsy pathway and multidisciplinary care improve outcomes. AHA Journals

(Additional supportive measures—such as salt-sparing cooking skills, symptom diaries, and caregiver education—are often layered on by multidisciplinary teams.) JACC

---

Drug treatments

IMPORTANT: Dosing must be individualized by your specialist; the snippets below reflect label or common trial-based practice and are not medical advice.

1. Tafamidis (Vyndaqel/Vyndamax) — TTR stabilizer
   Use: First-line disease-modifying therapy for ATTR-CM to reduce death and CV hospitalizations.
   Dose/time: 61 mg tafamidis free acid once daily (or 80 mg meglumine).
   How it works: Stabilizes the TTR tetramer so it doesn’t fall apart and form amyloid.
   Evidence/notes: ATTR-ACT showed lower mortality and hospitalizations over 30 months; benefits across EF spectrum. Side effects: generally mild (GI symptoms). PubMed+1

2. Acoramidis (Attruby™) — next-gen TTR stabilizer
   Use: Approved (US, 2024) to reduce CV death and CV hospitalization in ATTR-CM.
   Dose/time: Per label (oral, twice daily with food; follow current label).
   How it works: Strongly stabilizes TTR tetramer (kinetic stabilizer).
   Evidence/notes: ATTRibute-CM showed improved outcomes; 2025 OLE suggests sustained CV mortality reduction. Side effects generally mild (GI). American College of Cardiology+2Reuters+2

3. Vutrisiran (AMVUTTRA®) — RNAi TTR silencer
   Use: FDA-approved March 20, 2025 for ATTR-CM; also approved for hATTR polyneuropathy.
   Dose/time: 25 mg subcutaneous every 3 months.
   How it works: Small interfering RNA knocks down liver TTR production → less amyloid.
   Evidence/notes: HELIOS-B showed lower all-cause death/CV events and better function/QoL vs placebo; pooled safety favorable. Injection-site reactions and mild lab changes most common. Reuters+2PubMed+2

4. Patisiran (ONPATTRO®) — RNAi TTR silencer
   Use: Approved for hATTR polyneuropathy; not yet approved for ATTR-CM, but APOLLO-B showed preserved 6MWD/QoL at 12 months.
   Dose/time: IV infusion q3 weeks (PN indication).
   Evidence/notes: Consider in trials/specialist settings; infusion reactions possible. New England Journal of Medicine+1

5. Eplontersen (WAINUA™) — antisense oligonucleotide silencer
   Use: FDA-approved for hATTR polyneuropathy; has Fast Track for ATTR-CM (not approved for CM as of today).
   Dose/time: 45 mg SC monthly (PN indication).
   Notes: Specialist decision; ongoing CM programs. AstraZeneca+1

6. Loop diuretics (Furosemide/Torsemide/Bumetanide) — symptom relief
   Use: Cornerstone for fluid control (legs/lungs).
   Dose/time: Adjust to weight and symptoms; torsemide often favored for bioavailability.
   Notes: Watch kidney function and electrolytes. ijcscardiol.org

7. Mineralocorticoid receptor antagonists (Spironolactone/Eplerenone)
   Use: Add-on to diuretics for volume control and potassium sparing.
   Mechanism: Blocks aldosterone; reduces congestion.
   Notes: Monitor potassium/creatinine; gynecomastia with spironolactone. ijcscardiol.org

8. SGLT2 inhibitors (e.g., Dapagliflozin, Empagliflozin)
   Use: Growing interest in CA; may aid decongestion and outcomes in HF broadly; evidence in ATTR-CM evolving.
   Notes: Discuss with amyloid team; data not yet definitive for ATTR-CM. ijcscardiol.org

9. Amiodarone
   Use: Rhythm control for AF/atrial flutter when symptomatic.
   Notes: Useful when rate-slowing drugs are not tolerated; requires thyroid/liver/lung monitoring. Frontiers

10. Anticoagulants (DOACs/warfarin)
    Use: Stroke prevention in AF/flutter or atrial thrombus.
    Notes: Amyloid patients often need anticoagulation; follow guideline-based risk assessment. American College of Cardiology

11. Midodrine (select patients)
    Use: Symptomatic orthostatic hypotension limiting therapy.
    Notes: Use cautiously under specialist care. JACC

12. Doxycycline + tauroursodeoxycholic acid (TUDCA)
    Use: Investigational/adjunct in some centers; evidence low-quality and inconsistent.
    Notes: Not standard of care; consider only in trials or specialist protocols. PMC

13. Iron repletion (if iron-deficient)
    Use: Treats anemia that worsens dyspnea/fatigue.
    Notes: Correcting true deficiencies helps symptoms, but “supplements” without deficiency are not helpful. professional.heart.org

14. Thyroid replacement (if hypothyroid)
    Use: Corrects low thyroid that can mimic/worsen HF.
    Notes: Dose carefully to avoid tachyarrhythmias. AHA Journals

15. Careful use/avoidance of standard HF drugs
    Use: ACEi/ARB/ARNI and high-dose beta-blockers often poorly tolerated; use only if clear benefit and tolerated.
    Notes: Digoxin historically cautioned; may be used in select cases with close monitoring. AHA Journals+1

(Your amyloidosis team chooses from the above to fit your symptoms, blood pressure, kidneys, and rhythm.)

---

Dietary molecular supplements” — reality check

There is no supplement proven to treat ATTR-CM. Major guidelines caution against routine vitamins/supplements for heart failure unless you have a true deficiency. Focus on salt restriction, whole-food patterns, and deficiency correction only. Examples your team may consider if you are deficient: (1) Iron (IV or oral if iron-deficient), (2) Vitamin D if low, (3) B12/folate for macrocytosis or neuropathy, (4) Thiamine if malnourished or high diuretics, (5) Magnesium if low with arrhythmias/diuretics. High-dose unproven supplements can harm kidneys or interact with medicines. professional.heart.org

---

Immunity-booster / regenerative / stem-cell” drugs

No immune-booster or stem-cell drug is approved for ATTR-CM. The most exciting regenerative-style approach is gene silencing (vutrisiran, patisiran, eplontersen) and gene editing (NTLA-2001) that lowers TTR production at the liver. NTLA-2001 (in vivo CRISPR-Cas9) has shown deep, durable TTR reductions after a single IV dose in early studies, including a cardiomyopathy arm—but it remains investigational. Participation in reputable clinical trials at amyloidosis centers is the safe path for such therapies. IntelliATX+3Reuters+3PubMed+3

---

Procedures/surgeries

1. Pacemaker
   Why: For symptomatic bradycardia or advanced conduction block (common in ATTR-CM). Helps maintain heart rate if the native conduction system fails. American College of Cardiology

2. Implantable cardioverter-defibrillator (ICD)
   Why: Considered case-by-case (clear benefit not consistent in amyloidosis). Generally used after life-threatening ventricular arrhythmia or per standard HF indications. American College of Cardiology+1

3. Catheter ablation for atrial fibrillation
   Why: Rhythm control when medicines are not enough or poorly tolerated. May reduce symptoms and hospitalizations. Frontiers

4. Heart transplantation
   Why: For advanced, refractory heart failure in carefully selected ATTR-CM patients; outcomes at experienced centers can be comparable to other transplant indications. PMC+1

5. Combined heart–liver transplant (rare)
   Why: Historically used in some hereditary ATTR to remove the liver source of variant TTR along with replacing the failing heart; used selectively today. PMC

---

Prevention & self-care tips

1. Stay on low-salt food plan. 2) Track daily weight and symptoms. 3) Take medicines exactly as prescribed. 4) Avoid NSAIDs unless your doctor approves. 5) Keep vaccines current. 6) Treat sleep apnea. 7) Tell your team about palpitations or fainting quickly. 8) Keep a current medication and allergy list. 9) Encourage adult relatives to consider TTR testing once your diagnosis is confirmed. 10) Keep regular follow-ups at an amyloidosis-experienced center. JACC

---

When to see a doctor urgently

• Fast weight gain (≥2 kg in 3 days), severe breathlessness, chest pain, fainting, new rapid or very slow heartbeat, confusion, inability to keep food/fluids down, or markedly swollen legs/abdomen. These can signal decompensated heart failure or dangerous arrhythmia and need urgent evaluation. JACC

---

FAQs

1) Is V122I the same as Val142Ile?
Yes—two naming systems for the same variant in the TTR gene. NCBI

2) How common is the V122I variant?
About 3–4% of Black/African-ancestry individuals in the U.S.; risk of HF rises with age. PMC+1

3) Does every carrier get disease?
No. Penetrance is age-dependent and incomplete, but risk is clearly higher than non-carriers. AHA Journals

4) What is the best first test if ATTR-CM is suspected?
Echo with strain + monoclonal protein screen → then 99mTc-PYP (or DPD/HMDP) scan with SPECT when AL is excluded. AHA Journals+1

5) Do I still need a heart biopsy?
Often no, if the nuclear scan is grade 2/3 and AL screen is negative (non-biopsy pathway). AHA Journals

6) What medicines change the course of disease?
TTR stabilizers (tafamidis, acoramidis) and silencers (vutrisiran—FDA-approved for ATTR-CM in 2025) have outcome data. PubMed+2American College of Cardiology+2

7) Is patisiran approved for ATTR-CM?
Not currently; APOLLO-B showed functional benefits but regulatory approval for CM has not been granted to date. New England Journal of Medicine

8) Why are beta-blockers or some calcium-channel blockers a problem?
Amyloid hearts depend on heart rate to maintain output; rate-slowing drugs can worsen symptoms or BP. Use is cautious and individualized. AHA Journals

9) Do supplements help?
Routine supplements don’t treat ATTR-CM. Correct only true deficiencies (iron, B12, etc.). professional.heart.org

10) Can gene editing cure it?
CRISPR (NTLA-2001) shows deep TTR knock-down in early trials, but it’s still investigational. PubMed

11) Should my family get tested?
Yes, offer genetic counseling and TTR testing to adult relatives. NCBI

12) What’s the role of MRI if I already had a PYP scan?
MRI (T1/ECV) helps quantify burden, look for scar, and may support prognosis/response. PMC

13) Will I need a pacemaker or ICD?
Pacemakers are common for conduction disease; ICDs are individualized because survival benefit isn’t consistent in amyloidosis. American College of Cardiology

14) Can people live long with modern therapy?
Outcomes have improved since tafamidis and now acoramidis/vutrisiran; earlier diagnosis brings better stability. PubMed+2American College of Cardiology+2

15) What everyday habit makes the biggest difference?
Meticulous fluid and salt management plus sticking to your amyloidosis medicines. ijcscardiol.org

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 28, 2025.